

## AMENDMENTS

### In the Claims

Claims 32-43 are pending.

Claim 41 is amended as follows:

Claims 1-31 (canceled).

32. (previously presented) A method of diagnosing colorectal cancer comprising:

- a) determining the expression of a nucleic acid sequence at least 95% identical to SEQ ID No:1 in a first sample comprising colorectal cancer cells from a first individual; and
- b) comparing the expression of said nucleic acid sequence in the first sample to expression of said nucleic acid sequence in a second sample taken from either normal colon tissue of said first individual or from normal colon tissue, or a bodily secretion of a second unaffected individual;

wherein a difference between the expression in the first sample and the expression in the second sample indicates that the first individual has colorectal cancer.

33. (previously presented) The method of claim 32, wherein said second sample is from said first individual.

34. (previously presented) The method of claim 33, wherein said first sample is colorectal tissue.

35. (previously presented) The method of claim 33, wherein said second sample is colorectal tissue.

36. (previously presented) The method of claim 33, wherein said second sample is cancerous tissue.

37. (previously presented) The method of claim 32, wherein said second sample is from a second individual.

38. (previously presented) The method of claim 37, wherein said first sample is colorectal tissue.

39. (previously presented) The method of claim 37, wherein said second sample is colorectal tissue.

40. (previously presented) The method of claim 37, wherein said second sample is cancerous tissue.

41. (currently amended) The method of claim 32, wherein said ~~gene~~ nucleic acid sequence is SEQ ID NO:1.

42. (previously presented) The method of claim 32, wherein said expression is measured using a labeled nucleic acid probe.

43. (previously presented) The method of claim 32, wherein said expression is measured utilizing a biochip.

Claims 44-47 (canceled).